$4.45
0.45% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US62855J1043
Symbol
MYGN

Myriad Genetics, Inc. Stock price

$4.45
-2.95 39.86% 1M
-10.85 70.92% 6M
-9.26 67.54% YTD
-20.56 82.21% 1Y
-17.52 79.75% 3Y
-10.16 69.54% 5Y
-30.00 87.08% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.02 0.45%
ISIN
US62855J1043
Symbol
MYGN
Sector
Industry

Key metrics

Market capitalization $410.19m
Enterprise Value $475.99m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.57
P/S ratio (TTM) P/S ratio 0.49
P/B ratio (TTM) P/B ratio 0.58
Revenue growth (TTM) Revenue growth 7.38%
Revenue (TTM) Revenue $831.30m
EBIT (operating result TTM) EBIT $-89.10m
Free Cash Flow (TTM) Free Cash Flow $-24.00m
Cash position $91.80m
EPS (TTM) EPS $-1.12
P/E forward negative
P/S forward 0.51
EV/Sales forward 0.59
Short interest 8.56%
Show more

Is Myriad Genetics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Myriad Genetics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Myriad Genetics, Inc. forecast:

4x Buy
24%
9x Hold
53%
4x Sell
24%

Analyst Opinions

17 Analysts have issued a Myriad Genetics, Inc. forecast:

Buy
24%
Hold
53%
Sell
24%

Financial data from Myriad Genetics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
831 831
7% 7%
100%
- Direct Costs 270 270
5% 5%
33%
561 561
15% 15%
67%
- Selling and Administrative Expenses 478 478
4% 4%
57%
- Research and Development Expense 113 113
24% 24%
14%
-29 -29
50% 50%
-4%
- Depreciation and Amortization 60 60
7% 7%
7%
EBIT (Operating Income) EBIT -89 -89
27% 27%
-11%
Net Profit -101 -101
57% 57%
-12%

In millions USD.

Don't miss a Thing! We will send you all news about Myriad Genetics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Myriad Genetics, Inc. Stock News

Neutral
GlobeNewsWire
6 days ago
SALT LAKE CITY, May 14, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that management plans to participate in the following investor healthcare conferences: The BofA Securities 2025 Health Care Conference – fireside chat at 6:00 pm ET (updated) on Wednesday, May 14, 2025. Goldman Sachs 46 th Annual...
Neutral
Business Wire
12 days ago
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON MYRIAD GENETICS, INC. (MYGN),...
Neutral
Business Wire
12 days ago
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN MYRIAD GENETICS, INC. (MYGN), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING ...
More Myriad Genetics, Inc. News

Company Profile

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to asses an individual's risk of developing a disease later in life. The Other segment offers products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients; and also includes corporate services such as finance, human resources, legal, and information technology. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Head office United States
CEO Samraat Raha
Employees 2,700
Founded 1991
Website www.myriad.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today